StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)

Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%

Johnson & Johnson ZYTIGA [reported separately through FY2025Q4] by Quarter

ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — Worldwide operational (constant-currency) growth YoY (%) (%)

QuarterlyAnnual

Johnson & Johnson ZYTIGA [reported separately through FY2025Q4]: -13.0% in Q4 2025, up 16.6 pts from a year earlier.

Latest, Q4 2025
-13.0%
Period ended Dec 28, 2025
Change on a year earlier
+16.6 pts
-29.6% in Q4 2024
History
33 quarters
Since Q4 2017
Sources
33
Documents cited below

Where the Q4 2025 figure comes from

“|| WW | 119 | 135 | (11.9) | (13.0) | 1.1”

Source: Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗

Reported in Form 8-K EX-99.2 Segment Sales Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — Worldwide operational (constant-currency) growth YoY (%) (%)Year on yearSource
Q4 2025Dec 28, 2025-13.0%+16.6 ptsForm 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
Q3 2025Sep 28, 2025-26.8%+0.7 ptsForm 8-K (a2025q3exhibit991.htm, filed 2025-10-14) ↗
Q2 2025Jun 29, 2025-14.9%+7.0 ptsForm 8-K (a2025q2exhibit991.htm, filed 2025-07-16) ↗
Q1 2025Mar 30, 2025-28.3%-6.2 ptsForm 8-K (a2025q1exhibit991.htm, filed 2025-04-15) ↗
Q4 2024Dec 29, 2024-29.6%-4.3 ptsForm 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗
Q3 2024Sep 29, 2024-27.5%+25.7 ptsForm 8-K (a2024q3exhibit991.htm, filed 2024-10-15) ↗
Q2 2024Jun 30, 2024-21.9%+31.9 ptsForm 8-K (a2024q2exhibit991.htm, filed 2024-07-17) ↗
Q1 2024Mar 31, 2024-22.1%+28.8 ptsForm 8-K (a2024q1exhibit991.htm, filed 2024-04-16) ↗
Q4 2023Dec 31, 2023-25.3%+18.3 ptsForm 8-K (a2023q4exhibit991.htm, filed 2024-01-23) ↗
Q3 2023Oct 1, 2023-53.2%-50.6 ptsForm 8-K (a2023q3exhibit991.htm, filed 2023-10-17) ↗
Q2 2023Jul 2, 2023-53.8%-54.7 ptsForm 8-K (a2023q2exhibit991.htm, filed 2023-07-20) ↗
Q1 2023Apr 2, 2023-50.9%-40.8 ptsForm 8-K (a2023q1exhibit991.htm, filed 2023-04-18) ↗
Q4 2022Jan 1, 2023-43.6%-35.7 ptsForm 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗
Q3 2022Oct 2, 2022-2.6%+4.9 ptsForm 8-K (a2022q3exhibit991.htm, filed 2022-10-18) ↗
Q2 2022Jul 3, 20220.9%+8.0 ptsForm 8-K (a2022q2exhibit991.htm, filed 2022-07-19) ↗
Q1 2022Apr 3, 2022-10.1%+2.8 ptsForm 8-K (a2022q1exhibit991.htm, filed 2022-04-19) ↗

Breakdown

What makes up ZYTIGA [reported separately through FY2025Q4]

Cite this data

StockData. (2026). Johnson & Johnson ZYTIGA [reported separately through FY2025Q4] (%), quarterly Q4 2017–Q4 2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-zytiga-ops-yoy

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.